These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Ho DD; Neumann AU; Perelson AS; Chen W; Leonard JM; Markowitz M Nature; 1995 Jan; 373(6510):123-6. PubMed ID: 7816094 [TBL] [Abstract][Full Text] [Related]
3. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection. Wilkins E J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268 [No Abstract] [Full Text] [Related]
4. HIV-1 dynamics in vivo: implications for therapy. Simon V; Ho DD Nat Rev Microbiol; 2003 Dec; 1(3):181-90. PubMed ID: 15035022 [TBL] [Abstract][Full Text] [Related]
5. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects]. Marcello A; Giacca M Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891 [No Abstract] [Full Text] [Related]
6. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Chun TW; Engel D; Mizell SB; Hallahan CW; Fischette M; Park S; Davey RT; Dybul M; Kovacs JA; Metcalf JA; Mican JM; Berrey MM; Corey L; Lane HC; Fauci AS Nat Med; 1999 Jun; 5(6):651-5. PubMed ID: 10371503 [TBL] [Abstract][Full Text] [Related]
7. Predictors of virologic response to ritonavir-boosted protease inhibitors. Marcelin AG; Flandre P; Peytavin G; Calvez V AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962 [TBL] [Abstract][Full Text] [Related]
8. [HIV-1 quantitative dynamics in vivo: a review of mathematical models]. Le Corfec E; Rouzioux C; Costagliola D Rev Epidemiol Sante Publique; 2000 Apr; 48(2):168-81. PubMed ID: 10804426 [TBL] [Abstract][Full Text] [Related]
9. HIV-1 and HAART: a time to cure, a time to kill. Saag MS; Kilby JM Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490 [No Abstract] [Full Text] [Related]
10. Decay characteristics of HIV-1-infected compartments during combination therapy. Perelson AS; Essunger P; Cao Y; Vesanen M; Hurley A; Saksela K; Markowitz M; Ho DD Nature; 1997 May; 387(6629):188-91. PubMed ID: 9144290 [TBL] [Abstract][Full Text] [Related]
11. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials. Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278 [TBL] [Abstract][Full Text] [Related]
12. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196 [TBL] [Abstract][Full Text] [Related]
14. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil. Vergara TR; Estrela RC; Suarez-Kurtz G; Schechter M; Cerbino-Neto J; Barroso PF Ther Drug Monit; 2006 Apr; 28(2):175-9. PubMed ID: 16628127 [TBL] [Abstract][Full Text] [Related]
17. Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors. Bermejo M; Sánchez-Palomino S; Usán L; Alcamí J J Med Virol; 2004 Aug; 73(4):502-7. PubMed ID: 15221892 [TBL] [Abstract][Full Text] [Related]
18. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331 [TBL] [Abstract][Full Text] [Related]
20. [Efficacy of ritonavir in HIV positive patients pretreated with nucleoside analogues]. Gómez-Cano M; Soriano V; Polo R; Valencia E; Adrados M; González-Lahoz J An Med Interna; 1998 Feb; 15(2):83-6. PubMed ID: 9542203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]